• Latest Posts

Gene editing to make French fries less unhealthy

Back to Middle Age to re-discover some medicinal treatments

The Strategic Focus of Roche-Genentech on Personal Genetic data

Anergis completed Phase II for AllerT, a novel treatment for pollen allergies

Interview with CELLPROTHERA, the regenerative medicine pioneer

ADVERTISEMENT

Cardio3 will launch an IPO in the United States

Merck Serono and Intrexon, to develop CAR-T Therapy

#BioFigures: €406 Million Antibody-drug conjugate Deal struck by ImmunoGen andTakeda

Strategic Partnership Between Green Cross and Nanolek

With €200 Million, Cellectis is on its way to make the Biggest French Biotech IPO ever

ADVERTISEMENT